Quantum BioPharma Ltd. (NASDAQ: QNTM) is moving its lead compound, Lucid-MS, into a randomized, double-blind, placebo-controlled Phase 2 trial for multiple sclerosis (MS) after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application. The milestone positions the company to test a novel mechanism that could address a significant unmet need in MS treatment.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Unlike current MS therapies that primarily suppress the immune system, Lucid-MS is designed to target demyelination directly. Myelin degradation is the underlying mechanism of MS, and preventing or reversing it could potentially slow or halt disease progression. Preclinical models have shown Lucid-MS to prevent and reverse myelin degradation, according to the company.
The FDA's clearance of the IND application allows Quantum BioPharma to proceed with clinical testing in humans, a critical step toward potential regulatory approval. If successful, Lucid-MS could offer a new treatment paradigm for MS patients who do not respond adequately to existing therapies or who seek alternatives with different safety profiles.
Quantum BioPharma is also collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. This imaging tool could enhance the evaluation of therapies like Lucid-MS by providing objective biomarkers of myelin repair. The collaboration underscores the company's commitment to advancing both therapeutic and diagnostic approaches for neurodegenerative disorders.
The broader biopharmaceutical landscape has seen recent progress in areas of unmet medical need. Novartis AG (NYSE: NVS) received FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA(TM) accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a Phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
For Quantum BioPharma, the advancement of Lucid-MS into Phase 2 represents a key inflection point. The company is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on Lucid-MS. Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights. The agreement includes a 7% royalty on sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
